Soluble CD40 ligand in haemodialysis patients: survival impact and cardiovascular prognostic role

References

• Aloui C, Prigent A, Garraud O. (2014). The signaling role of CD40 ligand in platelet biology and in platelet component transfusion. Int J Mol Sci 15:22342–64.
   PubMed Web of Science ®Google Scholar
• Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. (2003). Membrane-associated CD40L and sCD40l in atherothrombotic disease. Thromb Haemost 90:377–84.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Bakogiannis C, Tousoulis D, et al. (2009). The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54:669–77.
   PubMed Web of Science ®Google Scholar
• Appel LJ. (2004). Beyond (or back to) traditional risk factors: preventing cardiovascular disease in patients with chronic kidney disease. Ann Intern Med 140:60–1.
   PubMed Web of Science ®Google Scholar
• Aukrust P, Müller F, Ueland T, et al. (1999). Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614–20.
   PubMed Web of Science ®Google Scholar
• Bhadra R, Gigley JP, Khan IA. (2011). Cutting edge: CD40-CD40 ligand pathway plays a critical, CD8-intrinsic and -extrinsic role during rescue of exhausted CD8 T cells. J Immunol 187:4421–5.
   PubMed Web of Science ®Google Scholar
• Campean V, Neureiter D, Nonnast-Daniel B, et al. (2007). CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Atherosclerosis 190:156–66.
   PubMed Web of Science ®Google Scholar
• Chen C, Chai H, Wang X, et al. (2008a). Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 112:3205–16.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen J, Xiong Y, et al. (2006b). Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun 345:106–17.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Chiarelli F, Davì G, et al. (2005). Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 48:1216–24.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Mezzetti A, Porreca E, et al. (2002). Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106:399–402.
   PubMed Web of Science ®Google Scholar
• Derks W, Lutgens E, van Bilsen M, Heymans S. (2013). CD40-CD40 ligand (CD40L) signaling modulates cardiac hypertrophy in angiotensin-II induced hypertensive heart disease. FASEB J 27:1128–36.
   Google Scholar
• Desideri G, Ferri C. (2003). Effects of obesity and weight loss on soluble CD40L levels. JAMA 289:1781–2.
   PubMed Web of Science ®Google Scholar
• Desideri G, Ferri C. (2005). Endothelial activation. Sliding door to atherosclerosis. Curr Pharm Des 11:2163–75.
   PubMed Web of Science ®Google Scholar
• Desideri G, Panichi V, Paoletti S, et al.; RISCAVID investigators. (2011). Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up. Nephrol Dial Transplant 26:2983–8.
   PubMed Web of Science ®Google Scholar
• Elgueta R, Benson MJ, de Vries VC, et al. (2009). Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152–72.
   PubMed Web of Science ®Google Scholar
• Ferroni P, Guadagni F. (2008). Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc Hematol Disord Drug Targets 8:194–202.
   PubMedGoogle Scholar
• Graf D, Müller S, Korthäuer U, et al. (1995). A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 25:1749–54.
   PubMed Web of Science ®Google Scholar
• Haller ST, Kalra PA, Ritchie JP, et al. (2013). Effect of CD40 and sCD40l on renal function and survival in patients with renal artery stenosis. Hypertension 61:894–900.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm CW, et al.; CAPTURE Study Investigators. (2003). Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–11.
   PubMed Web of Science ®Google Scholar
• Hocher B, Liefeldt L, Quaschning T, et al. (2007). Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. J Am Soc Nephrol 18:1323–30.
   PubMed Web of Science ®Google Scholar
• Jefferis BJ, Whincup PH, Welsh P, et al. (2011). Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case–control study of older men and women. J Thromb Haemost 9:1452–9.
   PubMed Web of Science ®Google Scholar
• Kacso IM, Lenghel A, Patiu IM, et al. (2010). Prognostic value of plasma adiponectin in type 2 diabetic dialysis patients. Clin Pharmacol Ther 14:205–11.
   Google Scholar
• Lajer M, Tarnow I, Michelson AD, et al. (2010). Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets 21:525–32.
   PubMed Web of Science ®Google Scholar
• Lim PS, Wu MY, Chien SW, et al. (2008). Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease. Nephrology (Carlton) 13:677–83.
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487–501.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. (2004). Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagul Fibrinolysis 15:463–7.
   PubMed Web of Science ®Google Scholar
• Packard RRS, Libby P. (2008). Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 54:24–38.
   PubMed Web of Science ®Google Scholar
• Panichi V, Rizza GM, Paoletti S, et al. (2008). Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant 23:2337–43
   PubMed Web of Science ®Google Scholar
• Panichi V, Scatena A, Migliori M, et al. (2012). Biomarkers of chronic inflammatory state in uremia and cardiovascular disease. Int J Inflam 2012:360147. doi: 10.1155/2012/360147.
   Google Scholar
• Patel JV, Lim HS, Nadar S, et al. (2006). Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 24:117–21.
   PubMed Web of Science ®Google Scholar
• Penno G, Pucci L, Dell'omo G, et al. (2009). Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. Am J Hypertens 22:1007–13.
   PubMed Web of Science ®Google Scholar
• Ritz E, McClellan WM. (2004). Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far reaching consequences. J Am Soc Nephrol 15:513–16.
   PubMed Web of Science ®Google Scholar
• Schönbeck U, Varo N, Libby P, et al. (2001). Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–8.
   PubMed Web of Science ®Google Scholar
• Sirolli V, Strizzi L, Di Stante S, et al. (2001). Platelet activation and platelet erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Haemost 86:834–9.
   PubMed Web of Science ®Google Scholar
• Sonmez A, Dogru T, Yilmaz MI, et al. (2005). Soluble CD40 ligand levels in patients with hypertension. Clin Exp Hypertens 27:629–34.
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Navaneethan SD, Johnson DW, et al. (2008). Effects of statins in patients with chronic kidney disease: meta-analysis and meta regression of randomized controlled trials. Br Med J 336:645–51.
   PubMed Web of Science ®Google Scholar
• Tagawa M, Hamano T, Nishi H, et al. (2014). Mineral metabolism markers are associated with myocardial infarction and hemorrhagic stroke but not ischemic stroke in hemodialysis patients: a longitudinal study. PLoS One 9:e114678. doi: 10.1371/journal.pone.0114678.
   Google Scholar
• Tentori F, Blayney MJ, Albert JM, et al. (2008). Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 5:519–30.
   Web of Science ®Google Scholar
• Tripepi G, Mallamaci F, Zoccali C. (2005). Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16:S83–S8.
   PubMed Web of Science ®Google Scholar
• Verma S, Wang CH, Li SH, et al.; FATE Investigators. (2005). The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis 182:361–5.
   PubMed Web of Science ®Google Scholar
• Vishnevetsky D, Kiyanista VA, Gandhi PJ. (2004). CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother 38:1500–8.
   PubMed Web of Science ®Google Scholar
• Yuan M, Ohishi M, Wang L, et al. (2010). Association between serum levels of soluble CD40/CD40 ligand and organ damage in hypertensive patients. Clin Exp Pharmacol Physiol 37:848–51.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wu T, Chen M, et al. (2013). The CD40/CD40L system: a new therapeutic target for disease. Immunol Lett 153:58–61.
   PubMed Web of Science ®Google Scholar